In addition, the possibility of cytoprotective properties afforded by DPP-4 inhibitors on organs/tissues which are affected by diabetes (such as the heart, vessels, kidneys, and retina) and associated with serious diabetic complications might open new avenues for the use of these agents in the treatment of diabetic patients. The gene discussed is DPP4; the disease is diabetes mellitus.